Inflazome

Inflazome is a leading biopharmaceutical company pioneering the advancement of orally accessible medications to tackle unaddressed medical requirements in inflammatory ailments by focusing on inflammasomes. These inflammasomes are recognized to stimulate numerous persistent inflammatory disorders, including but not limited to, Parkinson's and Alzheimer's diseases, asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis, and NASH. Inflazome possesses two investigational drugs in the clinical stage of development.